A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation (+XMatch DDKTx)

Trial Profile

A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation (+XMatch DDKTx)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2016

At a glance

  • Drugs Eculizumab (Primary) ; Immunosuppressants
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 28 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
    • 16 Apr 2014 According to NCT record eculizumab doses has been changed from 600 mg to 900 mg for day 1 and weekly treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top